NeuroBo Gets IRB Green Light for Phase 1 Obesity Drug Trial

NeuroBo Pharmaceuticals, based in Cambridge, Mass., announced that it has received IRB approval for its Phase 1 clinical trial of DA-1726, targeting obesity. The trial will be conducted under the supervision of Dr. Alexander Prezioso at Clinical Pharmacology of Miami in Hialeah, FL. The company plans to commence patient randomization in the second quarter of the year.

DA-1726 is a dual oxyntomodulin analog agonist that activates GLP1R and GCGR receptors, potentially offering better tolerability than existing GLP-1 agonists. In preclinical mouse models, DA-1726 demonstrated superior weight loss compared to medications like semaglutide (Wegovy®) and tirzepatide (Zepbound™).

The Phase 1 trial will be a two-part study involving single ascending doses (SAD) and multiple ascending doses (MAD) in obese but otherwise healthy subjects. Approximately 45 participants will be enrolled in the SAD part, and around 36 participants in the MAD part. The study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726. Adverse events and pharmacokinetic profiles will be closely monitored.

The company's CEO, Hyung Heon Kim, expressed optimism about the trial, emphasizing the potential benefits of DA-1726 in the treatment of obesity. Top-line data from Part 1 of the trial is expected in the first half of 2025, with results from Part 2 anticipated in the second half of 2025.NeuroBo Pharmaceuticals continues its mission to transform cardiometabolic disease treatments with innovative investigational therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!